Jeff Evans on Muck Rack

Jeff Evans

Verified
  • Editor, Rheumatology News, MDEdge
Raleigh
As seen in: MDEdge, MDPI, The Hill, Medscape, The Post-Crescent, Clinical Neurology News, Internal Medicine News, MDedge | Cardiology News, MDedge Dermatology, MDedge Neurology, MdEdge ObGyn and
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Jeff

Contact Jeff, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

Tildrakizumab Now Under FDA Review for Psoriatic Arthritis Indication

|
By Jeff Evans Verified
| Medscape Verified
The manufacturer of the interleukin-23 inhibitor tildrakizumab (Ilumya), Sun Pharma, announced today that the FDA has accepted its supplemental biologics license application for the indication of active psoriatic arthritis (PsA) in adults. The manufacturer said it expects to have a decision from the agency by October 29, 2026.
Open in Who Shared Issue with article?

FDA Approves Deucravacitinib as First TYK2 Inhibitor for PsA

|
By Jeff Evans Verified
| Medscape Verified
Deucravacitinib (Sotyktu) — an oral, selective tyrosine kinase 2 (TYK2) inhibitor — has received FDA approval for the treatment of adults with active psoriatic arthritis (PsA), the drug’s manufacturer Bristol Myers Squibb announced. The drug is the first TYK2 inhibitor to be approved for treating PsA. Deucravacitinib was first approved by the FDA in 2022 for the treatment of adults with moderate-to-severe plaque psoriasis who are candidates for systemic therapy or phototherapy.
Open in Who Shared Issue with article?

FDA Approves Third-Ever Drug for Lupus Nephritis

|
By Jeff Evans Verified
| Medscape Verified
The FDA approved Genentech’s CD20-targeting antibody obinutuzumab (Gazyva) for the treatment of adult patients with lupus nephritis who are receiving standard therapy.
Open in Who Shared Issue with article?
See all 192 articles
 •  Privacy  •  Terms  •  Security and Legal  •   •   •   • 

© 2026 Muck Rack

SOC 2® Certified